Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The SURMOUNT-1 trial showed 22.5% average weight loss with tirzepatide at 15 mg, compared to 14.9% with semaglutide at 2.4 mg in the STEP-1 trial
The company said it halted the research after discovering that the most promising agent posed a cardiovascular risk for individuals with a particular genetic defect. The company did not disclose the name of the agent
Like Alices discoveries in Wonderland, we found disproportionate reporting signals for several medications, including methylphenidate in youths, and montelukast, aripiprazole, sertraline, and topiramate in adults
And the published study, while valuable, was retrospective, company-authored, and lacks a control group - limitations that any informed consumer should weigh alongside the results
Link, S
Choosing reputable compounding pharmacies with proper certifications helps minimize these risks
